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Humans began cultivating plants roughly 10,000 years ago when 
the estimated global population was 
less than 10 million (24). Early farmers 
had to learn which plants could be cul-
tivated and how plants could be im-
proved through breeding by trial and 
error (7). Evidence suggests that pro-
genitors of modern varieties of wheat 
and barley were first domesticated 
nearly 10,000 years ago in the Middle 
East. Soybeans were domesticated ap-
proximately 5,000 years ago and rice 
approximately 6,000 years ago in Asia. 
Early varieties of maize were grown in 
Central America nearly 9,000 years ago 
(12). Although varieties of these com-
mon crops are genetically diverse, ma-
jor changes in the genetics of domes-
ticated crops have been sporadic (e.g., 
soybean) (14). Modern common bread 
wheat is a hexaploid (6n) species that 
has three times as many chromosomes 
and genes as its probable wild pro-
genitor, while pasta wheat (durum) is 
tetraploid (4n). Hexaploid wheat vari-
eties were derived from naturally hy-
bridized grass family relatives repre-
sented by diploid (2n) and tetraploid 
(4n) species (8). 
Most of the genetic diversity that 
has improved agricultural production 
throughout the history of farming was 
developed through natural mutations 
and selective breeding. However, since 
the early 1900s plant scientists have 
used chemical and radiation mutagene-
sis to increase genetic diversity (18). We 
know that the majority of mutations are 
harmful, and plant breeders work hard 
to select only those that are beneficial. 
This process has helped feed a grow-
ing human population, which is esti-
mated to have been 300 million 2,000 
years ago and is now more than 7 bil-
lion. However, methods used in the past 
to improve agricultural production are 
unlikely to keep pace with the current 
growth rate of the human population. 
Growing Challenges for Food 
Production 
Norman Borlaug won the No-
bel Peace prize in 1970 for his efforts 
that led to the “green revolution:’ In a 
speech reviewing 60 years of agricul-
tural improvements (Table I), he cred-
ited improved plant genetics, increased 
use of irrigation, increased and efficient 
use of fertilizers, and increased mech-
anization as the major factors leading 
to the tripling of production of wheat 
and rice in Asia between 1960 and 2000 
(1). Historically, genetic changes have 
been achieved by introducing unknown 
changes in genes through crossbreeding 
with wild relatives, development of hy-
brid varieties, and mutations induced by 
chemicals or radiation followed by care-
ful breeding for selection. Borlaug noted 
that more precise genetic modifica-
tion (GM) technology will be needed to 
maintain a sufficient food supply to feed 
the growing human population, which 
is expected to reach 10 billion by 2050. 
Today, agricultural and food sup-
ply systems around the world are being 
challenged by political and economic 
barriers that are slowing or blocking the 
introduction of commonly consumed 
varieties of plants and animals that 
have been improved by highly specific 
GM. This is occurring at a time when the 
world population continues to grow, 
per capita consumption of resources 
is growing even faster, and prime ag-
ricultural land is being converted to ur-
ban or industrial uses. In addition, grow-
ing concerns about the environmental 
risks associated with the use of chemical 
pesticides, herbicides, and fertilizers are 
pushing farmers to reduce inputs that 
have helped raise productivity over the 
past 100 years. Fewer people are willing 
or able to work as farmers, and meet-
ing growing demands requires contin-
ued improvements in the efficiency of 
food production. Rising food costs asso-
ciated with crop production on marginal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
farmland, crop failures due to changing 
weather patterns, high transportation 
costs, and energy use could be partly 
mitigated by the improvements in ag-
ricultural efficiencies offered by some 
GM crops. While there is a growing de-
mand for and supply of organic foods, 
it is not clear that organic methods can 
meet current and future demands and 
supplant industrial agriculture, which 
has become the dominant production 
method. In addition, some GM variet-
ies have been demonstrated to reduce 
the need for applied chemical pesti-
cides and, thus, are environmentally 
beneficial. 
As the human population contin-
ues to grow, we are not only increas-
ingly converting farmland to urban uses, 
more people are eating meat, which is 
not energetically efficient. To compen-
sate, we need to increase the rate of 
crop improvements, and as argued by 
Norman Borlaug, we need to use all 
available genetic tools, in cluding bio-
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technology (genetic engineering), and 
improve use of chemical fertilizers, wa-
ter, and mechanization to meet grow-
ing demands. 
Importance of Genetic Complexity 
and Diversity of Non-GM Plants 
Genetic diversity is essential to al-
low efficient growth of crops under di-
verse environmental conditions (e.g., 
day length, temperature, moisture 
level, soil type, pests, and disease con-
ditions). Significant increases in yield 
have been achieved by combining dif-
ferent genetic types in parent lines and 
even more through hybrid generation 
from 1930, when the average corn pro-
duction in the United States was 30 bu/
acre, to 2004, when the average was 
150 bu/acre (25). Hybrids of corn are 
produced by crossing genetically di-
verse parents to produce high-yield-
ing seeds that generally outperform in-
bred line yields. Although hybrid seeds 
cost more, the increased yield usually 
pays farmers a dividend. Recent work 
also has demonstrated that inbred pa-
rental lines have substantial genetic di-
versity (33). 
While great improvements have 
been made possible by advanced mo-
lecular breeding and selection, the in-
troduction of genes from other spe-
cies has opened up the possibility of 
developing plants that could never be 
achieved through breeding alone (e.g., 
resistance to the European corn borer 
and corn rootworm by the introduc-
tion of genes from the bacterium Ba-
cillus thuringiensis). The safety of bac-
terial pesticides has been studied, and 
they are regulated by the U.S. Environ-
mental Protection Agency (EPA)—the 
same agency that now regulates insect-
resistant GM crops (23). The methods 
of using plant breeding, genetic engi-
neering, and organic farming should be 
complementary, and the safety assess-
ment of biopesticides should be simi-
lar because the active ingredients are 
the same. 
Introducing New Traits Through 
Biotechnology 
Watson and Crick won the Nobel 
Prize in 1963 for describing the basic 
structure of DNA polymers in 1953 (37). 
DNA is made up of unique extended 
sequence arrangements of four simple 
nucleotides (ATGC). They suggested a 
model structure of amino acids defined 
by a triple nucleotide codon arrange-
ment, which with the anti-parallel DNA 
strands allowed accurate replication of 
the chromosomes. Of course, more de-
tails were later identified by other scien-
tists (36). Understanding the structure of 
DNA was essential to enable biotech-
nology, and work by other scientists 
was necessary to develop many of the 
molecular tools used in the 1960s and 
early 1970s that led to the production of 
the first specifically genetically modified 
plants in the 1970s. 
Contribution of GM Plants to the 
Food and Fiber Supply 
Scientists around the world have 
been developing potentially useful GM 
crops since the early 1990s. Many of 
these GMOs will never be used com-
mercially because they will fail to func-
tion, will not meet regulatory health 
or environmental safety criteria, or the 
value of the crop would not meet the 
costs of development and regulatory 
studies. However, some could be suc-
cessful. The area of land cultivated in 
GM crops in 2012 surpassed 160 million 
hectares (17). Almost all of the approved 
GM plants have been invented or the 
rights purchased by large corporations 
with sufficient infrastructure and capital 
to complete registrations. Information 
about specific plants, crops, and ap-
provals is available from the Center for 
Environmental Risk Assessment (CERA) 
(3) and the International Service for the 
Acquisition of Agri-biotech Applications 
(16). CERA lists 109 GMOs approved for 
food or feed in the United States, in-
cluding alfalfa, canola, chicory, cotton, 
flax, linseed, maize, papaya, plum, po-
tato, sugar beet, tomato, and wheat. A 
number of these GMOs are not currently 
commercially available (e.g., GM wheat). 
In the United States, 88% of corn, 
94% of cotton, and 93% of soybeans 
grown are GM varieties (35). The dom-
inant GM traits are herbicide tolerance 
and insect resistance. Genes for the pri-
mary insect resistance traits have come 
from a bacterium (B. thuringiensis) that 
farmers have used as an organic pesti-
cide since the 1940s (31). Insect-resis-
tant plants reduce the need for chem-
ical insecticides. A few viral resistance 
traits have been introduced that have 
reduced crop losses due to plant patho-
gens such as Papaya ringspot virus, Po-
tato leafroll virus, and Potato yellows vi-
rus (3). However, a number of GMOs 
that were approved in the United States 
between 1995 and 2013 have not been 
approved for growing or importation in 
many parts of the European Union and 
some other countries, even though they 
were tested prior to commercial release 
and found to be as safe as convention-
ally produced varieties using evaluations 
recommended by the Codex Alimentar-
ius Commission guidelines (4). 
New GM developments include nu-
tritionally enhanced commodity crops 
that can provide essential vitamins or 
precursors (e.g., rice and maize with 
high 13-carotene contents), as well as 
minerals (e.g., rice with high iron con-
tent), at lower costs compared with al-
ternative food supplements. The Gates 
Foundation (www.gatesfoundation.org), 
the US. Agency for International De-
velopment (USAID), HarvestPlus, and 
other organizations are working to in-
crease food security and nutrient avail-
ability using a variety of techniques to 
improve food crops, including genetic 
modification.  
General Food Safety 
The US. Food and Drug Adminis-
tration (FDA) recognizes that all foods 
have inherent risks for some individu-
als. For example, individuals with diabe-
Table 1. Factors in the “green revolution” from 1961 to 2000* 
                       Adoption of Modern Varieties     Total Cereal
                    (million ha (% total growing area))  Irrigation Area  Fertilizer Use  Tractors  production 
Year  Wheat  Rice  (million ha)  (million tons)  (million)  (million tons) 
1961**  0(0)  0(0)  87  2  0.2  309 
1970  14 (20)  15 (20)  106  10  0.5  463 
1980  39 (49)  55 (43)  129  29  2.0  618 
1990  60 (70)  85 (65)  158  54  3.4  858 
2000  70 (84)  100 (74)  175  70  4.8  962 
* Adapted from Borlaug (1). 
** Source: FAOSTAT (July 2002) and Borlaug’s estimaled adoption (1) based on International Maize and Wheat Improvement Center (CIM-
MYT) and International Rice Research Institute (IRRI) data. 
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tes must restrict their sugar intake. Indi-
viduals with insufficient lactase enzyme 
experience diarrhea and bloating if they 
consume products that contain lactose 
(i.e., dairy products). Individuals with ce-
liac disease (1-2% of the global popu-
lation) must avoid gluten proteins from 
wheat, barley, and rye to prevent ongo-
ing damage to their upper small intes-
tine and potentially more serious auto-
immunity, malnutrition, and/or cancer. A 
few individuals with IgE-mediated food 
allergies must avoid the foods that trig-
ger their disease or risk experiencing se-
vere anaphylaxis and potentially death. 
Other consumers with food allergies ex-
perience less severe symptoms. Many 
legume species must be cooked to in-
activate lectins, protease, or amylase in-
hibitors and prevent malabsorption or 
pain and diarrhea. The FDA has required 
food labels for ingredients and nutri-
ents for many years. However, passage 
of the Food Allergy Labeling and Con-
sumer Protection Act (FALCPA) by the 
U.S. Congress in 2006 created additional 
regulations for labeling of allergens and 
celiac-eliciting food ingredients. 
FDA Regulation of GM Plants 
The FDA published a policy state-
ment concerning the safety assess-
ment of foods derived from GM crops 
(organisms) in 1992 (6), stating that re-
combinant DNA plants would be regu-
lated within the existing Federal Food, 
Drug and Cosmetic Act. As stated, a GM 
plant having similar components (pro-
teins, fats, oils, and carbohydrates) as 
a non-GM counterpart and no appar-
ent risk from the inserted gene and ex-
pressed new protein is treated as a nor-
mal constituent and does not require 
special labeling. However, if there is any 
indication of a new risk, the novel ingre-
dient must be treated as a food addi-
tive. The 1992 FDA policy (6) provided 
the EPA with lead-agency responsibility 
for GMOs with pesticidal proteins and 
the U.S. Department of Agriculture lead-
agency responsibility in the case of GM 
meat or poultry. The policy clearly states 
that these agencies will work in a coop-
erative manner, with the FDA having ul-
timate authority on food safety. The pri-
mary focus of the policy guidelines is to 
determine whether a new protein pres-
ents a new potential risk of allergenicity 
or toxicity. In addition, the safety charac-
teristics of the gene donor organism and 
the host organism (gene recipient) must 
be considered with regard to potential 
characteristics related to food safety. 
Before gaining regulatory approval, 
developers of GMOs must supply study 
data verifying that their GMO products 
are safe. Based on the safety record and 
benefits provided by their approved 
GMO products, biotech companies are 
seeing GM seed sales rise, and the tech-
nology has gained wide acceptance by 
farmers. Of course, any agricultural prac-
tice has an impact on the environment, 
but in general GMOs are no more haz-
ardous than their non-GM counterparts. 
Evaluation and Regulation Based on 
Food Safety Principles 
Before any GM plants were approved 
and released commercially in 1996, sci-
entists from diverse disciplines were dis-
cussing opportunities, risks, and appro-
priate controls for the technology (2,13). 
The International Food Biotechnology 
Council (IFBC) was formed in 1988 and 
brought together “150 representatives of 
government agencies from 13 countries, 
industrial scientific organizations, profes-
sional societies, congressional-legislative 
staffs, public interest-consumer groups 
and academicians” from the food and 
biotechnology industries to draft a food 
safety document covering the general 
topic of the safety of foods derived from 
biotechnology (22). The full recommen-
dations were published in a supplement 
to volume 12 of Regulatory Toxicology 
and Pharmacology (15). The consensus 
was that GM crops should be regulated 
within the legal and regulatory frame-
work of foods and food additives that 
was developed over more than 80 years. 
The IFBC agreed that the primary task 
is to characterize the potential risk of a 
new protein or trait and to ensure that 
foods derived from the GMO are sub-
stantially equivalent to non-GM counter-
parts, at least within the range of com-
monly used nonGM varieties of the same 
species. The assessment strategy was re-
fined further in scientific consultations, 
culminating with a Codex Alimentarius 
guideline published in 2003 and repub-
lished in 2009 (4). 
This 2003 Codex document laid the 
foundation for regulation of GM prod-
ucts in the United States, Canada, Japan, 
and the international treaty members 
of the Codex Alimentarius Commission 
and was updated with minor revisions in 
2009 (4). The guidelines recognize that 
all foods pose some risks for some in-
dividuals. The 4-6% of individuals world-
wide with food allergies must avoid the 
specific foods that cause their reactions, 
while those without allergies can safely 
consume the same food (30). By the same 
token, individuals with celiac disease (1-
2% of the world population) must avoid 
gluten proteins from wheat, barley, and 
rye (19,29). The primary concern for food 
developers is to avoid transferring a ma-
jor allergen or potentially cross-reactive 
protein into a new food source. 
Understanding the Technical 
Changes Introduced through 
Biotechnology 
Although basic science courses pro-
vide knowledge on the structure of ge-
netic material, reproduction, synthe-
sis of proteins, and general physiology, 
many consumers do not understand the 
basic science behind biotechnology or 
that the products of genetic modifica-
tion are predictable based on the nu-
cleotide and protein sequences of the 
new trait. At the same time, the scien-
tists who develop GMOs and the reg-
ulators who evaluate their safety must 
understand the subject in sufficient de-
tail to ensure the proper functioning of 
a GMO and to understand the fidelity 
and nonrandom nature of living organ-
isms. To bridge this gap, we as scientists 
must learn to communicate to consum-
ers the concepts, reliability, and ade-
quacy of the safety assessments used 
to ensure that GMOs are safe. 
It is difficult for consumers to find 
simply stated information that describes 
the extensive premarket testing required 
for GMO products. Social and commer-
cial news media sources frequently pres-
ent polarized positions regarding the 
benefits, safety, and dangers of GMOs, 
often portraying reports of adverse ef-
fects as truthful and failing to mention 
the extensive literature and evidence 
supporting GMO safety. 
It is important that consumers un-
derstand that unless they are intended 
to be different from their non-GM coun-
terparts (e.g., as Golden Rice differs 
from regular rice) GMOs are the same 
in terms of their food safety and nutri-
tional properties. As a result, the basic 
principles of food safety and food safety 
evaluation used for nonGM foods are 
fully capable of detecting any hazards 
associated with GM foods. 
Characterizing the GMO DNA Insert 
and Function 
The GMO developer must demon-
strate appropriate function of the in-
serted gene, expression of the protein, 
and appropriate function of the specific 
new GMO. The DNA may be inserted 
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in many different regions of the host 
DNA, as long as it functions appropri-
ately and does not disrupt other essen-
tial functions. Sometimes multiple cop-
ies are inserted into the chromosomes 
or insertion may occur at more than one 
location. Construction of the transfor-
mation vector and gene cassette must 
be defined and the method of inser-
tion specified. The flanking sequence 
at the point of insertion is character-
ized to identify any unexpected or fu-
sion proteins that might be expressed in 
the GMO that were not expressed in the 
non-GM host. Newer vectors and meth-
ods of controlling insertion are being 
developed and used, but it is important 
to realize that many processes are pat-
ented, and the techniques used in the 
1990s are still scientifically acceptable 
for new products developed in 2014. 
Thus, if an independent scientist devel-
ops a new GM using older technology, 
it should be allowed if the product is 
proven safe and effective. 
Characterizing the New Proteins 
Consideration of potential risks is 
focused primarily on the safety of the 
new protein. The evaluation process 
begins by considering the possible his-
tory of safe (or unsafe) human expo-
sure to the gene source. Extra testing 
may be required for genes taken from 
sources that are commonly allergenic 
or toxic, depending on whether there is 
information regarding the safety of the 
specific protein encoded by the gene. 
The amino acid sequence as expressed 
in the GMO must be verified, and the 
structure and function of the newly ex-
pressed protein are evaluated as well. 
Evaluating Potential Allergenicity of 
GMOs 
Few foods cause severe allergic re-
actions, and very few proteins within 
those foods are responsible for sensiti-
zation and elicitation. For example, there 
are four major allergenic proteins found 
in peanuts, and these proteins are abun-
dant. Peanut allergy is thought to cause 
~50–80 deaths per year in the United 
States in consumers who are allergic and 
unsuccessful in avoiding peanuts in the 
foods they consume. Soybean, which is 
estimated to cause less than one fatal 
allergic reaction per year in the United 
States, contains eight or nine moderately 
allergenic proteins in its seeds. 
It is important to prevent the transfer 
of an allergenic protein from food air-
way, contact, or injection sources into 
a new food that an allergic consumer 
would not recognize as containing the 
allergen. For instance, transferring the 
allergenic 2S albumin Ara h 2 from pea-
nut into rice would put many people 
who are allergic to peanut at risk of se-
vere reactions. It is relatively easy, how-
ever, to identify most of the important 
risks of transferring food allergens if a 
few simple steps are followed. This was 
demonstrated in 1996 (26) by the eval-
uation of the protein from a Brazil nut 
gene that was transferred into soybean 
to increase its nutritional properties 
for agricultural animals—a case where 
substantial risk was possible. The tests 
were performed because the source 
of the gene is known to cause allergic 
reactions in some individuals. Today, 
more allergens have been identified and 
added to databases such as AllergenOn-
line, and a similar protein would have 
been flagged as a likely allergen requir-
ing serum IgE testing due to high se-
quence identity matches to other aller-
genic 2S albumins (described below). 
The steps required for the assess-
ment of GM crop allergenicity have of-
ten been misinterpreted, or the risks 
have been overemphasized (11). Un-
doubtedly the most important step is 
a bioinformatics search to compare the 
sequence to those of known allergens 
using a well-characterized allergen da-
tabase (10). AllergenOnline (also termed 
the FARRP database by some; http://
www.AllergenOnline.org ) currently 
is the only peer-reviewed, sequence 
searchable database available for pub-
lic use. It is updated annually, and ver-
sion 14 (released January 2014) includes 
1,706 sequences in 645 taxonomic 
groups. The sequences are selected 
based on criteria to evaluate data pub-
lished to demonstrate IgE binding, us-
ing clinically defined serum donors and 
test method criteria. Sequences in the 
NCBI Protein database — http://www.
ncbi.nlm.nih.gov/guide/proteins — may 
also be used for comparison using key 
word limits (e.g., allerg*, allergen, or al-
lergenicity), but the user is then respon-
sible for evaluating the relevance of any 
match: there are more than 52,000 se-
quences in the database that are asso-
ciated with the key word “allergen” (as 
of April 26, 2014), and for many, there 
is no proof of IgE binding or causing re-
actions. The most informative search is 
a full-length alignment, and if the new 
GM protein matches a known allergen 
with >50% identity and a very small E 
score, the alignment is likely to show 
cross-reactive IgE binding and pos-
sibly shared allergic elicitation. How-
ever, allergens are not equal in potency 
or frequency of elicitation. In addition, 
the Codex guidelines (4) recommend 
searching for matches of >35% identity 
over any alignment of 80 or more amino 
acids using either the FASTA or BLASTP 
programs (4). In addition, many coun-
tries expect a short identity match com-
parison that looks for segments of eight 
contiguous amino acids that match any 
allergen. However, there are a number 
of publications that demonstrate a short 
segment match is not predictive (32). 
If the GM protein aligns with an al-
lergen at >35% identity over 80 or 
more amino acids, serum IgE binding 
tests would normally be required, using 
sera from donors that are clinically de-
fined with the appropriate allergies and 
validated methods (9,11). Some pro-
teins identified in AllergenOnline or in 
other publications rarely cause any al-
lergic reaction. It will prove impossible 
to find qualified donors for such pro-
teins, but for them the risk of allergic 
reaction to the GM protein is likely to 
be extremely low. Additional consider-
ations include the need to use sera from 
subjects with other allergies as nega-
tive control donors to ensure that IgE 
binding is specific and also to use pos-
itive and negative control antigens (9). 
If binding is observed, it is usually in-
formative to perform specific inhibition 
tests to validate the specificity of bind-
ing. If the GMO developer wants to pro-
ceed with a product that has some pos-
itive binding, it is necessary to evaluate 
the biological relevance of the binding 
using basophil activation or histamine 
release. Alternatively, in vivo skin prick 
tests or other challenges would be ap-
propriate, although it is essential to con-
sider whether the potential risk to the 
patients is warranted (11). 
Additional steps in the Codex guide-
lines (4) are more relevant for determin-
ing whether a new protein might become 
an allergen based on the characteristics 
of many known food allergens. Or alter-
natively, they may be used in consider-
ing appropriate risk assessment and mit-
igation steps if the protein is determined 
to be an allergen after approval. The sta-
bility of the protein in pepsin and un-
der heating conditions may be useful in 
the initial evaluation because many ma-
jor food allergens are relatively abun-
dant and stable in pepsin at pH 2. Stabil-
ity in heat means the protein maintains 
its three-dimensional form and function 
when cooked at “normal” cooking tem-
peratures. Many major food allergens are 
also quite abundant in a food. Therefore, 
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pepsin and heat-stable, abundant pro-
teins may pose a risk of sensitization in 
the future, although there are a number 
of very stable and abundant proteins that 
do not cause food allergies. It would be 
extremely useful to have a predictive an-
imal model or cell culture system (e.g., 
dendritic cells, T cells, and B cells) for ac-
curate evaluation of the sensitizing po-
tential of novel proteins. However, no an-
imal model, cell culture method, complex 
protease digestion protocol, or computer 
prediction modeling has yet been dem-
onstrated to accurately predict the risk of 
sensitization for humans (20,21). 
Evaluating Potential Toxicity of 
GMOs 
The Codex guidelines call for evalu-
ation of the potential toxicity of a pro-
tein (4). In their review, Delaney et al. (5) 
provide an interesting model for safety 
evaluation for potential toxicity. It is 
based on the source of the gene (i.e., 
whether it is likely to be toxic or not) 
and a bioinformatics match to known 
toxic proteins or enzymes that make 
toxic metabolites. A history of safe use 
or human exposure is a key compo-
nent of a toxicity evaluation. There are 
very few proteins that are toxic when 
ingested, such as botulinum and ri-
cin, which are highly toxic. Even pro-
teins with fairly high identity matches 
to these proteins are not known to 
be toxic (unpublished data). There are 
many “toxic” proteins from stinging in-
sects, snakes, and other organisms, but 
many of them are unlikely to cause tox-
icity if consumed at low concentrations. 
A comparison of the GM protein by 
BLASTP to the NCBI protein database us-
ing key word limits “toxic” or “toxin” will 
identify significant matches to toxic pro-
teins. There are no absolute criteria for 
this search, so it is important to use rel-
ative comparisons if a significant match 
is found (e.g., >50% identity over most 
of the length of the protein, with an E 
score smaller than 1e-15). In this case a 
BLASTP search using the GM protein with 
no key word might identify proteins with 
a history of safe use and high identity 
to the GM protein. A search comparing 
the matched toxin to other proteins in 
the NCBI database also would be instruc-
tive. If the gene is from a toxic sequence 
source and matches a toxin with mod-
est identity, then specific tests should be 
performed based on the toxic character-
istics of the protein (e.g., neurotoxin for 
many snake and spider venoms or liver 
toxicity for some mycotoxins). Some 
countries require an acute mouse gavage 
with the protein if the GM protein is in-
secticidal (e.g., EPA) through oral admin-
istration at high dose followed by obser-
vation of clinical signs for 14 days before 
sampling for blood chemistry. The mice 
are then killed, and their organs are ana-
lyzed for differences in weight compared 
with control mice and for gross pathol-
ogy and, when appropriate, histopathol-
ogy following good laboratory practices. 
Some governments require a 90 day, 
rat whole-feeding study for most GM 
crop products. In this case, groups of 
rats are fed diets with a high inclusion 
rate of the GM crop material and identi-
cal doses of non-GM crop material from 
genetically similar varieties. Additional 
commercial non-GM varieties are used 
with groups of rats to evaluate minor sta-
tistical differences that might be due to 
chance. This is not a true toxicity study, 
but a nutritional equivalence study. 
There is no need to perform chronic 
studies or multigeneration studies un-
less there is a scientifically justified ra-
tionale to suggest the GM product or 
protein is likely to have long-term ef-
fects. In my opinion, the currently ap-
proved GM products (109 in the United 
States) do not have characteristics that 
would warrant such tests. In any test 
that is intended to identify potential 
toxicity, there must either be a history 
that the test can predict a toxic effect in 
humans or an animal species of concern, 
or positive and negative control test ar-
ticles must be included in the study to 
evaluate the biological relevance of any 
noted difference(s). 
Analysis of Nutritional Adequacy 
Specific foods are consumed to sup-
ply nutrients. Humans are omnivores 
and can develop and survive on highly 
varied diets. However, we generally are 
concerned with feeding nutritionally ad-
equate diets to agricultural species (e.g., 
chickens, cows, fish, and pigs) that have 
restricted diets. Therefore, it is impor-
tant to ensure that the nutritional prop-
erties of a GMO are similar to those of 
non-GM varieties intended for similar 
use. In most cases, simple proximate 
analysis is all that is necessary, using 
samples from multiple field trial sites. 
However, for specific crops there may 
be specific nutrients (e.g., vitamins, min-
erals, and fatty acids) or antinutrients 
(e.g., phytate, lectins, amylase, or pro-
tease inhibitors) that are monitored to 
verify “safety.” If the new GM protein is 
an enzyme that is active in the plant, it 
is important to evaluate specific metab-
olites based on the functional properties 
of the enzyme and the metabolic path-
ways in the host (gene recipient). For ex-
ample, Monsanto evaluated the impact 
of inserting the enzyme CP4 EPSPS in 
its Roundup Ready soybean because the 
enzyme is known to produce metabo-
lites that lead to the formation of aro-
matic amino acids, flavonoids, and other 
aromatic amino acids or isoflavones. No 
significant differences were found be-
tween non-GM and herbicide-toler-
ant Roundup Ready soybeans (27,34). 
Some future GM crops are intended to 
have changes in their nutrient profIles. 
For example, Golden Rice 2 (GR2) ex-
presses high levels of β-carotene due to 
the insertion of two genes that express 
enzymes essential for the synthesis of 
β-carotene (28). Non-GM rice does not 
normally express β-carotene (also called 
provitamin A). To make a health claim 
that GR2 has the potential to provide 
sufficient provitamin A, the developers 
had to demonstrate a substantial accu-
mulation of the compound and associ-
ated α-carotene in the rice grain (28). 
Conclusions 
To date, there is no proof of harm 
to humans or farm animals from con-
sumption of approved GM varieties of 
plants. To maximize efficiency and mini-
mize costs, the safety evaluation process 
for food and feed should be the same in 
all countries. It is unfortunate that there 
isn’t a mechanism for global approval 
because the current system leads to 
long delays in global trade of commod-
ities and finished food products. The 
process also adds costs when reports 
and, in some cases, duplicate studies are 
performed. It is also clear that generi-
cally labeling foods as “GMO” will not 
provide any relevant health benefit, be-
cause any possible harm will be product 
specific, and the dose and, thus, expo-
sure will vary markedly between prod-
ucts. Labeling only provides a way to 
discriminate against a technology with 
many important benefits. To combat un-
substantiated concerns, it is clear that 
scientists need to develop more effec-
tive methods of communicating with 
the public to provide assurances about 
the safety of foods produced from ap-
proved GM varieties. 
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